Dan Leonard
Stock Analyst at UBS
(2.44)
# 2,272
Out of 4,829 analysts
287
Total ratings
52.2%
Success rate
-6.58%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECH Bio-Techne | Maintains: Buy | $95 → $70 | $49.94 | +40.17% | 11 | May 9, 2025 | |
| BRKR Bruker | Maintains: Neutral | $57 → $45 | $37.52 | +19.94% | 11 | May 8, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $185 | $148.99 | +24.17% | 14 | May 7, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $238.68 | +29.88% | 20 | May 2, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $234.41 | +32.25% | 20 | May 2, 2025 | |
| GH Guardant Health | Maintains: Buy | $65 → $70 | $41.72 | +67.79% | 9 | May 1, 2025 | |
| RVTY Revvity | Upgrades: Buy | $145 → $115 | $91.25 | +26.03% | 2 | May 1, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $715 → $500 | $403.13 | +24.03% | 15 | Apr 24, 2025 | |
| DHR Danaher | Maintains: Buy | $275 → $240 | $189.73 | +26.50% | 17 | Apr 23, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $8.77 | +59.64% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $12.02 | +107.99% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $138.79 | +33.29% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $7.07 | +27.30% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $420 → $350 | $299.21 | +16.97% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 | $11.98 | +33.56% | 9 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $19.70 | +77.66% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $106.93 | +40.28% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $75.76 | +163.99% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $1.99 | +454.16% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $151.95 | -53.93% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $51.63 | +74.32% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $9.03 | -22.48% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $344.06 | +0.27% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $133.96 | +94.09% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $176.96 | -18.06% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $56.75 | +58.59% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $41.86 | +52.05% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $245.73 | +38.36% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $24.00 | - | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,080.98 | +38.76% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $3.89 | +799.74% | 12 | Aug 14, 2019 |
Bio-Techne
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $49.94
Upside: +40.17%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $37.52
Upside: +19.94%
IQVIA Holdings
May 7, 2025
Maintains: Buy
Price Target: $255 → $185
Current: $148.99
Upside: +24.17%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $238.68
Upside: +29.88%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $234.41
Upside: +32.25%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $41.72
Upside: +67.79%
Revvity
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $91.25
Upside: +26.03%
Thermo Fisher Scientific
Apr 24, 2025
Maintains: Buy
Price Target: $715 → $500
Current: $403.13
Upside: +24.03%
Danaher
Apr 23, 2025
Maintains: Buy
Price Target: $275 → $240
Current: $189.73
Upside: +26.50%
10x Genomics
Feb 13, 2025
Maintains: Neutral
Price Target: $20 → $14
Current: $8.77
Upside: +59.64%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $12.02
Upside: +107.99%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $138.79
Upside: +33.29%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.07
Upside: +27.30%
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $299.21
Upside: +16.97%
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $11.98
Upside: +33.56%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $19.70
Upside: +77.66%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $106.93
Upside: +40.28%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $75.76
Upside: +163.99%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $1.99
Upside: +454.16%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $151.95
Upside: -53.93%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $51.63
Upside: +74.32%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $9.03
Upside: -22.48%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $344.06
Upside: +0.27%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $133.96
Upside: +94.09%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $176.96
Upside: -18.06%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $56.75
Upside: +58.59%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $41.86
Upside: +52.05%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $245.73
Upside: +38.36%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $24.00
Upside: -
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,080.98
Upside: +38.76%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $3.89
Upside: +799.74%